Celltrion and Samsung Bioepis’s follow-on biosimilars are gaining momentum in the global market. A total of 11 biosimilars from the two companies are being prepared for their launch into the global market.

According to the industry on the 14th, Celltrion’s Avastin biosimilar is awaiting approval in the US and European market this year. Also, Samsung Bioepis’s Lucentis biosimilar eye drug, ‘Byooviz’ is preparing its release in the US market.

Also, 9 other biosimilars from the two companies that target trillion-won market items such as the psoriasis treatment ‘Stelara,’ macular degeneration treatment ‘Eylea,’ SKE treatment ‘Prolia’ are awaiting release into the global market. B